Dimerix Limited · ASX:DXB
Dimerix — Investor Presentation (November 2021)
19 slides from Dimerix's investor presentation, Nov 23, 2021
Slide 1: Investor Presentation November 2021
@ Dimerix (ASX:DXB) Investor Presentation November 2021 Authorised for lodgment by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: Board and management team
For personal use only Bronwyn Robert Nina Hamish Product Development R&D Director CEO & MD CFO & Co.Sec Director
Slide 4: About Dimerix
About Dimerix Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases Advancing three near-term Phase 3 clinical studies Demonstrated clinical efficacy*;
Slide 5: Top shareholders
For personal use only Top shareholders
Slide 6: Pathway towards commercialisation
Pathway towards commercialisation sal | | 1 ia v Phase 3 study in FSGS initiating, with N other pipeline products also progressing ._ Y Two independent Phase 3 clinical Pal > studies underway in patients with Pe .) COVID-19 respiratory complications nid oe \ q v DMX-200 manufacturing process optimis
Slide 7: Product candidates in the pipeline
5 product candidates in the pipeline, with 4 clinical opportunities For personal use only
Slide 8: DMX-200 — working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway Ang Il SARS-CoV-2 —_ on or DMX-200 pro-inflammatory gy Kidney cell cytokines damage AT1R ‘, * Small molecule — new chemical entity DMX-299 % ‘. — —“ #— . DMx-200 & : + Inhibits activity of a cellular receptor of inflammation: CCR2 Inflammatory *,
Slide 9: Kidney Disease Development Overview
For personal use only Kidney Disease Development Overview
Slide 10: FSGS phase study design
FSGS phase 3 study design Recruitment of first patient anticipated Q4 2021 A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB ly Part 1 (n="70) Recruit Part 1 DMX-200 + ARB Recruit Part 1 Final results Placeb
Slide 11: Why FSGS: unmet need and market potential
Why FSGS: unmet need and market potential FSGS: rare kidney disease characterized by inflammation and scarring of the kidney’s filtration units, affecting children and adults* Renal failure in <5 years from diagnosis — dialysis or transplant® “20,000 FSGS patients in US with end-stage kidney disease
Slide 12: COVID-19 Respiratory Complications
COVID-19 Respiratory Complications * For personai™ise Ona a
Slide 13: Potential benefits of DMX-200
Potential benefits of DMX-200 Antiviral medications: typically effective at preventing fil damage caused by a virus when % of administered ; within 3-5 days of infection (i 2 (when many are asymptomatic) DMX-200: \ does not rely on early inhibition of viral replication — DMX-200 aims to prevent dama
Slide 14: COVID-19 and pneumonia market potential
COVID-19 and pneumonia market potential 20-30% of all patients with pneumonia require admission to Intensive Care Units” 50 % Pneumonia is responsible for half of all cases of sepsis and septic shock* 3 million Deaths annually caused by lower respiratory tract infections pre-COVID* US$17 billion Pre
Slide 15: Two Phase studies in COVID-19 patients
Two Phase 3 studies in COVID-19 patients ey REMAP-CAP REMAP-CAP: COVID-19 pneumonia in ICU » >475 patients recruited to the study domain * WHO endorsed study * primary endpoint = 21 day mortality Funded by European Union through H2020 “Rapid European COVID-19 Emergency Research response” (RECOVER) p
Slide 16: Additional longer term propositions
Additional longer term propositions
Slide 17: Additional asset value propositions
Additional asset value propositions Longer term opportunities Diabetic Kidney Disease Chronic Obstructive Pulmonary Disease Diversifying risk and potential sources of revenue COPD Global COPD treatment market (2017) US$14 billion** Addressable market US$1.1 billion* Key driver is the rise in diabete
Slide 18: For personal use only
3x Og “- DD So Ajuo esn jeuosied 10]
Slide 19: For personal use only
For personal use only ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ❑ ❑ ❑ ❑ ❑ ❑ ❑